Table 3

Answers to multiple choice questions of survey section 1

QuestionsMultiple-choice responsesAll, n (%)H CPR, n (%)M CPR, n (%)L CPR, n (%)
N=75N=17N=51N=7
1. How do you triage your (CP-ICI) patients for SARS-CoV-2?☐ By telephone the day before the appointment13 (17.3)1 (5.9)12 (23.5)0 (0)
☐ Outside the hospital the same day of the clinic appointment15 (20)2 (11.8)9 (17.6)4 (57.1)
☐ By telephone the day before the appointment and outside the clinic the day of the appointment47 (62.7)14 (82.4)30 (58.8)3 (42.9)
2. Who among CP-ICI patients do you preferentially use telemedicine?☐ Patients in follow-up after finishing ICI adjuvant treatment7 (9.3)2 (11.8)5 (9.8)0 (0)
☐ Patients in follow-up who achieve complete response3 (4)2 (11.8)1 (2)0 (0)
☐ Both57 (76)11 (64.7)40 (78.4)6 (85.7)
☐ None of the above, I am not using telemedicine8 (10.7)2 (11.8)5 (9.8)1 (14.3)
3. How do you manage the new patients with cancer who need to start ICIs for metastatic disease?☐ Delay ICI start for COVID-19 in all patients0 (0)0 (0)0 (0)0 (0)
☐ Triage screening for COVID-19 risk factors69 (92)16 (94.1)46 (90.2)7 (100)
☐ Both2 (2.7)0 (0)2 (3.9)0 (0)
☐ None of the above4 (5.3)1 (5.9)3 (5.9)0 (0)
4. How do you manage the new patients with cancer who need to start ICIs for adjuvant purpose?☐ Delay ICI start for COVID-19 in all patients2 (2.7)1 (5.9)1 (2)0 (0)
☐ Triage screening for COVID-19 risk factors60 (0)15 (88.2)41 (80.4)4 (57.1)
☐ Both7 (9.3)0 (0)5 (9.8)2 (28.6)
☐ None of the above6 (8)1 (5.)4 (7.8)1 (14.3)
5. Do you have any CP-ICI who tested positive for SARS-CoV-2?☐ Yes21 (28)5 (29.4)16 (31.4)0 (0)
☐ No54 (72)12 (70.6)35 (68.6)7 (100)
6. If yes, how many?☐ <1024 (96)6 (100)18 (94.7)0 (0)
☐ 10–201 (4)0 (0)1 (5.3)0 (0)
☐ 20–500 (0)0 (0)0 (0)0 (0)
☐ 50–1000 (0)0 (0)0 (0)0 (0)
7. If yes, the most frequent CP-ICI SARS-CoV-2 positive are affected by?☐ Urogenital cancers5 (20)2 (33.3)3 (16)0 (0)
☐ Thoracic cancers14 (56)2 (33.3)12 (63)0 (0)
☐ Melanoma5 (20)1 (16.6)4 (21)0 (0)
☐ Head and neck cancers0 (0)0 (0)0 (0)0 (0)
☐ Other1 (4)1 (16.6)0 (0)0 (0)
8. How do you manage CP-ICI showing suspicious symptoms for COVID-19? (more than 1 option allowed)1. Order the SARS-CoV-2 test and continue with the ICIs avoiding delays3 (4)1 (5.9)2 (3.9)0 (0)
2. Suspend the ICIs while waiting for the test results22 (29.3)2 (11.8)18 (35.3)2 (28.6)
3. Ask for Rx thorax even in the absence of severe respiratory symptoms3 (4)1 (5.9)2 (3.9)0 (0)
4. Ask for thorax CT scan even in the absence of severe respiratory symptoms4 (5.2)1 (5.9)2 (3.9)1 (14.3)
5. Ask for blood test including: CBC, lactate dehydrogenase, high-sensitivity C reactive protein, interleukin-6, D-dimer1 (1.3)1 (5.9)0 (0)0 (0)
6. 2+57 (9.3)2 (11.8)3 (5.9)2 (28.6)
7. 2+37 (9.3)1 (5.9)6 (11.8)0 (0)
8. 2+3+510 (13.3)5 (29.4)5 (9.8)0 (0)
9. 2+3+41 (1.3)0 (0)1 (2)0 (0)
10. 2+47 (9.3)1 (5.9)5 (9.8)1 (14.3)
11. 2+4+511 (14.7)2 (11.8)8 (15.7)1 (14.3)
  • H CPR: high (H) prevalence regions with more than 10,000 positive patients, M CPR: medium (M) prevalence regions with positive patients less than 10,000 and more than 4000, L CPR: low (L) prevalence regions with less than 4000 positive patients.

  • CBC, complete blood count; CP, cancer patient; CP-ICI, cancer patients undergoing or candidate for immune checkpoint inhibitor; ICI, immune checkpoint inhibitor; N, number.